orismilast
Ulcerative Colitis
Key Facts
About UNION therapeutics
UNION therapeutics is a Danish clinical-stage biotech founded in 2017, targeting high-need immunological conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. Its lead asset, orismilast, is a PDE4 inhibitor in Phase 2 development, with recent data presented in ulcerative colitis and a novel biomarker profiling approach published. The company is privately funded, pre-revenue, and leverages a seasoned leadership team with deep drug development and commercialization experience to advance its pipeline.
View full company profileAbout UNION therapeutics
UNION therapeutics is a Danish clinical-stage biotech founded in 2017, targeting high-need immunological conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. Its lead asset, orismilast, is a PDE4 inhibitor in Phase 2 development, with recent data presented in ulcerative colitis and a novel biomarker profiling approach published. The company is privately funded, pre-revenue, and leverages a seasoned leadership team with deep drug development and commercialization experience to advance its pipeline.
View full company profileAbout UNION therapeutics
UNION therapeutics is a Danish clinical-stage biotech founded in 2017, targeting high-need immunological conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. Its lead asset, orismilast, is a PDE4 inhibitor in Phase 2 development, with recent data presented in ulcerative colitis and a novel biomarker profiling approach published. The company is privately funded, pre-revenue, and leverages a seasoned leadership team with deep drug development and commercialization experience to advance its pipeline.
View full company profileAbout UNION therapeutics
UNION therapeutics is a Danish clinical-stage biotech founded in 2017, targeting high-need immunological conditions such as atopic dermatitis, hidradenitis suppurativa, psoriasis, and ulcerative colitis. Its lead asset, orismilast, is a PDE4 inhibitor in Phase 2 development, with recent data presented in ulcerative colitis and a novel biomarker profiling approach published. The company is privately funded, pre-revenue, and leverages a seasoned leadership team with deep drug development and commercialization experience to advance its pipeline.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |